1. Advancing scientific knowledge on the epidemiology, pathophysiology, diagnosis, prevention, and treatment of MASLD.
2. Promoting high-level interdisciplinary collaboration among hepatologists, diabetologists, endocrinologists, and other specialists in related fields.
3. Supporting the dissemination of high-quality research and fostering translational approaches from basic science to clinical practice.
4. Encouraging international cooperation and the development of consensus frameworks within the field.
The MASLD Study group activities are unrestricted supported by Lilly®.
Researchers and clinicians with an interest in insulin resistance, diabetes, and cardiovascular disease are invited to join the MASLD Study Group.
MASLD membership provides access to scientific meetings and webinars, collaborative research opportunities, and MASLD-related publications and study initiatives.
MASLD to contribute to and engage with a European network dedicated to advancing research in insulin resistance. Please send your request to the following email: lucrecia.mota@med.unipi.it
The MASLD Study Group is an international scientific network composed of established clinical research groups, academic investigators, and expert collaborators, including partners from the pharmaceutical sector. The Group provides a structured and authoritative platform for the exchange of emerging scientific evidence through dedicated conferences, expert meetings, and collaborative initiatives.
Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly designated as NAFLD, represents the most prevalent chronic liver disorder in both the United States and Europe. MASLD may progress to metabolic dysfunction–associated steatohepatitis (MASH), a condition associated with a substantially increased risk of advanced fibrosis, cirrhosis, and hepatocellular carcinoma. As the hepatic manifestation of the metabolic syndrome, MASLD is highly prevalent among individuals with type 2 diabetes and other cardiometabolic disorders.
The MASLD Study Group serves as the official reference group of the European Association for the Study of Diabetes (EASD) for the scientific study of MASLD and its associated metabolic and hepatic complications.
